Pardoprunox clinical trials
How each study uses pardoprunox is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 3 |
| 2009 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Dopamine agonists source
- One of Serotonin receptor agonists source
Studies
Open first, then newest update. How each study uses pardoprunox is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.TerminatedPhase 2Abbott ProductsNCT00903838Written as pardoprunox
- An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.CompletedPhase 3Solvay PharmaceuticalsNCT00407095Written as Pardoprunox
- An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD PatientsCompletedPhase 3Solvay PharmaceuticalsNCT00335374Written as Pardoprunox
- Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's DiseaseCompletedPhase 3Solvay PharmaceuticalsNCT00134251Written as SLV308
- An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD PatientsCompletedPhase 3Solvay PharmaceuticalsNCT00332917Written as Pardoprunox
- SLV308 for Treatment of Patients With Early Parkinson's DiseaseCompletedPhase 3Solvay PharmaceuticalsNCT00269516Written as pardoprunox
Codes
What other systems call pardoprunox · ClinicalTrials.gg INT004602
- MeSH (NLM) C480679pardoprunoxOne source NLM
- UNII (FDA) 5R72CHP32SPARDOPRUNOXConfirmed FDA, NLM, Wikidata
- Wikidata Q27882143pardoprunoxConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C80765PardoprunoxOne source FDA
- DrugBank DB12061One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C480679 | pardoprunox | One source NLM |
| UNII (FDA) | 5R72CHP32S | PARDOPRUNOX | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27882143 | pardoprunox | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C80765 | Pardoprunox | One source FDA |
| DrugBank | DB12061 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.